Talimogene Laherparepvec
Brand names: Imlygic ยท Active ingredient: Talimogene Laherparepvec
In short: IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC has not been shown to improve overall survival or have an effe
What is Talimogene Laherparepvec used for?
IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Limitations
of use: IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.
Talimogene Laherparepvec dosage
For
intralesional injection only. Do not administer intravenously.
Administer IMLYGIC by injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound guidance.
IMLYGIC is provided in single-dose vials of 1 mL each in two different dose strengths:
106 (1 million) plaque-forming units (PFU) per mL (light green cap) โ for initial dose only
108 (100 million) PFU per mL (royal blue cap) โ for all subsequent doses
Recommended Dose and Schedule
The total injection volume for each treatment visit should not exceed 4 mL for all injected lesions combined. It may not be possible to inject all lesions at each treatment visit or over the full course of treatment. Previously injected and/or uninjected lesion(s) may be injected at subsequent treatment visits. The initial recommended dose is up to 4 mL of IMLYGIC at a concentration of 106
(1 million) PFU per mL. The recommended dose for subsequent administrations is up to 4 mL of IMLYGIC at a concentration of 108 (100 million) PFU per mL. The recommended dosing schedule for IMLYGIC is shown in Table 1.
Treatment | Treatment
I
nterval | Maximum
I
njection
V
olume
per
T
reatme
n
t
V
isit (all lesions combined) | Dose
S
trength | Prioritization of
L
esions to be
I
njected
Initial | โ | 4 mL | 106 (1 million)
PFU per mL | Inject largest lesion(s) first.
Prioritize injection of remaining lesion(s) based on lesion size until maximum injection volume is reached or until all injectable lesion(s) have been treated.
Second | 3 weeks after initial treatment | 4 mL | 108 (100 million)PFU per mL | Inject any new lesion(s) (lesions that have developed since initial treatment) first.
Prioritize injection of remaining lesion(s) based on lesion size until maximum injection volume is reached or until all injectable lesion(s) have been treated.
All subsequent treatments (including reinitiation) | 2 weeks after previous treatment | 4 mL | 108 (100 million)PFU per mL | Inject any new lesion(s) (lesions that have developed since previous treatment) first.
Prioritize injection of remaining lesion(s) based on lesion size until maximum injection volume is reached or until all injectable lesion(s) have been treated.
Dose Volume Determination (per Lesion)
Use Table 2 to determine the volume of IMLYGIC injection for each lesion.
Lesion
Size
(longest dimension) | Injection Volume
> 5 cm | up to 4 mL
> 2.5 cm to 5 cm | up to 2 mL
> 1.5 cm to 2.5 cm | up to 1 mL
> 0.5 cm to 1.5 cm | up to 0.5 mL
โค 0.5 cm | up to 0.1 mL
When lesions are clustered together, inject them as a single lesion according to Table 2.
Continue IMLYGIC treatment for at least 6 months unless other treatment is required or until there are no injectable lesions to treat. โฆ
How to take Talimogene Laherparepvec โ instructions & advice from the label
Advise patients and/or close contacts to:
Read the FDA-approved patient labeling (
Medication Guide
).
Follow instructions below to prevent viral transmission :โ Avoid direct contact with injection sites, dressings, or body fluids of patients.โ Wear gloves when changing dressing.โ Avoid touching or scratching injection sites.โ Keep injection sites covered for at least the first week after each treatment visit or longer if the injection site is weeping or oozing. Replace dressing if it falls off.โ Dispose of used dressings and cleaning materials in household waste in a sealed plastic bag.
Female patients of childbearing potential should use an effective method of contraception to prevent pregnancy during treatment with IMLYGIC
.
Close contacts who are pregnant or immunocompromised should not change dressings or clean injection sites
.
In case of accidental exposure to IMLYGIC, clean the exposed area with soap and water and/or a disinfectant. Patients or close contacts with suspected herpetic infections should contact their healthcare provider to evaluate the lesions. โฆ
Warnings & precautions
Do not take this medicine if: IMLYGIC is a live, attenuated herpes simplex virus and may cause life-threatening disseminated herpetic infection in patients who are immunocompromised. Do not administer IMLYGIC to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy .
Do not administer IMLYGIC to pregnant patients.
Accidental exposure may lead to transmission of IMLYGIC and herpetic infection. Accidental needle stick and splashback to the eyes have been reported in healthcare providers during preparation and administration of IMLYGIC.
Healthcare providers, close contacts (household members, caregivers, sex partners, or persons sharing the same bed), pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of treated patients . Healthcare providers who are immunocompromised or pregnant should not prepare or administer IMLYGIC.
Caregivers should wear protective gloves when assisting patients in applying or changing occlusive dressings and observe safety precautions for disposal of used dressings, gloves, and cleaning materials .
In the event of an accidental exposure to IMLYGIC, exposed individuals should clean the affected area thoroughly with soap and water and/or a disinfectant. If signs or symptoms of herpetic infection develop, the exposed individuals should contact their healthcare provider for appropriate treatment .
Patients should avoid touching or scratching injection sites or their occlusive dressings, as doing so could lead to inadvertent transfer of IMLYGIC to other areas of the body. โฆ
Talimogene Laherparepvec side effects
The most commonly reported adverse drug reactions (โฅ 25%) in IMLYGIC-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain.
The following adverse reactions are discussed in greater detail in another section of the label:
Herpetic Infection
Injection Site Complications
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of IMLYGIC was evaluated in 419 patients who received at least 1 dose of either IMLYGIC (n = 292) or subcutaneously administered granulocyte-macrophage colony-stimulating factor (GM-CSF) (n = 127) in an open-label, randomized clinical study of patients with stage IIIB, IIIC, and IV melanoma that was not considered to be surgically resectable . The median duration of exposure to IMLYGIC was 23 weeks (5.3 months). Twenty-six patients were exposed to IMLYGIC for at least 1 year.
Most adverse reactions reported were mild or moderate in severity and generally resolved within 72 hours. The most common grade 3 or higher adverse reaction was cellulitis .
Pyrexia, chills, and influenza-like illness can occur any time during IMLYGIC treatment but were more frequent during the first 3 months of treatment. โฆ
Drug interactions
IMLYGIC is sensitive to acyclovir. Acyclovir or other antiherpetic viral agents may interfere with the effectiveness of IMLYGIC. No drug interaction studies have been conducted with IMLYGIC.
About this medicine
IMLYGIC (talimogene laherparepvec) is a sterile suspension for intralesional injection. IMLYGIC is a live, attenuated HSV-1 that has been genetically modified to express huGM-CSF. The parental virus for IMLYGIC was a primary isolate, which was subsequently altered using recombinant methods to result in gene deletions and insertions.
Each vial contains 1 mL deliverable volume of IMLYGIC at either 1 x 106 (1 million) PFU per mL or 1 ร 108 (100 million) PFU per mL concentrations and the following excipients: di-sodium hydrogen phosphate dihydrate (15.4 mg), sodium dihydrogen phosphate dihydrate (2.44 mg), sodium chloride (8.5 mg), myo-inositol (40 mg), sorbitol (20 mg), and water for injection.
The 106 (1 million) PFU per mL vial of IMLYGIC contains a clear to semi-translucent liquid following thaw from its frozen state. The 108 (100 million) PFU per mL vial of IMLYGIC contains a semi-translucent to opaque liquid following thaw from its frozen state. The liquid in each vial may contain white, visible, variously shaped, virus-containing particles. โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 64ffb680-ea8c-42fc-9649-9e8c0eb77ddb. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate